WUXI XDC(02268),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02268 WUXI XDC

Trading 04-27 11:06:23

57.400

-0.650

-1.12%

High58.500	Low57.250	Vol718.50K
Open58.500	D1 Closing58.050	Amplitude2.15%
Mkt Cap72.32B	Tradable Cap72.32B	Total Shares1.26B
T/O41.41M	T/O Rate0.06%	Tradable Shares1.26B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"WUXI XDC","latestPrice":57.4,"timestamp":1777259180971,"preClose":58.05,"halted":0,"volume":718500,"delay":0,"changeRate":-0.011197243755383267,"floatShares":1260000000,"shares":1260000000,"eps":1.2854277662777303,"marketStatus":"Trading","change":-0.65,"latestTime":"04-27 11:06:23","open":58.5,"high":58.5,"low":57.25,"amount":41413737,"amplitude":0.021533,"askPrice":57.6,"askSize":13000,"bidPrice":57.4,"bidSize":24000,"shortable":3,"etf":0,"ttmEps":1.2835191338813445,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1777262400000},"marketStatusCode":2,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":58.05,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.847336,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02268/tweets","defaultTab":"tweets","newsList":[{"id":"1105341501","title":"WuXi XDC 2025 ESG Report: Revenue Up 46.70%, GHG Emission Intensity Down 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105341501","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105341501?lang=en_us&edition=fundamental","pubTime":"2026-04-24 17:26","pubTimestamp":1777022778,"startTime":"0","endTime":"0","summary":"WuXi XDC released its 2025 Environmental, Social and Governance (ESG) Report, outlining strong financial growth alongside marked improvements in sustainability metrics. Revenue climbed 46.70%...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134976330","title":"WuXi XDC 2025年度业绩速览：营收同比增长46.7%，多项业务与治理结构持续优化","url":"https://stock-news.laohu8.com/highlight/detail?id=1134976330","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134976330?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:52","pubTimestamp":1777020726,"startTime":"0","endTime":"0","summary":"根据WuXi XDC Cayman Inc.（简称“WuXi...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"WuXi XDC 2025年度业绩速览：营收同比增长46.7%，多项业务与治理结构持续优化","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629819965","title":"WuXi XDC publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629819965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629819965?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:47","pubTimestamp":1777020420,"startTime":"0","endTime":"0","summary":"WuXi XDC published its 2025 annual report, highlighting continued rapid expansion in bioconjugates CRDMO services.Business scale widened, with integrated iCMC projects rising to 252 as of Dec. 31, 2025, including 18 PPQ projects and 1 commercial project.Customer base expanded to more than 640 customers, with 14 of top 20 global pharmaceutical companies selecting WuXi XDC as a partner.Manufacturing footprint broadened across China, with Singapore site expected to achieve GMP release in H1 2026 under a global dual-sourcing strategy.R&D platform push continued, with focus on proprietary conjugation, linker, and payload-linker technologies including WuXiDARx, X-LinC, and WuXiTecan-2.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL1cMyvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823426480.USD","BK1576","LU0327786744.USD","LU1794554557.SGD","LU0417516902.SGD","LU1720050803.USD","LU0572944931.SGD","SG9999014674.SGD","LU0052750758.USD","LU0516423091.SGD","LU0979878070.USD","LU0140636845.USD","LU0856984785.SGD","LU0819121731.USD","LU1688375341.USD","LU0417516738.SGD","LU0181495838.USD","LU0320764599.SGD","02269","IE00B0JY6N72.USD","LU2039709279.SGD","LU0823426308.USD","LU1880383366.USD","LU0456846285.SGD","LU0039217434.USD","LU0348825331.USD","SG9999002562.SGD","SG9999002463.SGD","LU0326950275.SGD","LU0307460666.USD","BK1141","LU3063872942.SGD","LU0588546209.SGD","LU0456827905.SGD","LU0043850808.USD","LU2488822045.USD","LU0359201612.USD","LU0708995583.HKD","LU0516422952.EUR","LU0516422440.USD","LU0051755006.USD","LU1242518931.SGD","BK1589","LU0516422366.SGD","LU0516423174.USD","LU1242518857.USD","02268","BK1610","LU0359202008.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165196464","title":"HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165196464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165196464?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:32","pubTimestamp":1776915127,"startTime":"0","endTime":"0","summary":"HK biotech stocks fell. Akeso down 12%; Remegen, Zai Lab, KeyMed and Junshi down 7%; Lepu and Innocare down 6%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","02137","01672","06606","09966","02269","09926","09995","02162","03759","03347","02359","02268","09606","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133238716","title":"CMB International Reports Moderate Recovery in Healthcare Sector Risk Appetite, Recommends Six Stocks Including Hansoh Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=1133238716","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133238716?lang=en_us&edition=fundamental","pubTime":"2026-04-20 13:50","pubTimestamp":1776664224,"startTime":"0","endTime":"0","summary":"According to a research report from CMB International, the MSCI China Healthcare Index has risen 12.3% since the beginning of 2026, outperforming the MSCI China Index by 13.6%. Recent policy...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","159891","LU2097828714.EUR","LU2097828631.EUR","LU2242644610.SGD","01167","02268","BK1593","03692","LU2097828805.USD","LU2488822045.USD","LU2328871848.SGD","01530","LU2097828474.EUR","LU1969619763.USD","BK1191","01801","LU0455707207.USD","BK1589","LU0502904849.HKD","LU2097828557.USD","SG9999014674.SGD","BK1161","BK1574","BK1583","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626016437","title":"Assessing WuXi XDC Cayman (SEHK:2268) Valuation After New Akari Therapeutics ADC Partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2626016437","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626016437?lang=en_us&edition=fundamental","pubTime":"2026-04-10 12:55","pubTimestamp":1775796908,"startTime":"0","endTime":"0","summary":"Akari Therapeutics has entered a partnership with WuXi XDC Cayman (SEHK:2268) to support development of Akari’s PH1 payload and AKTX-101 program for metastatic urothelial cancer, further linking WuXi XDC to next generation ADC platforms.\nSee our latest analysis for WuXi XDC Cayman.\nInvestors appear to be weighing WuXi XDC’s new ADC partnership against a mixed share price pattern. The 30 day share price return of 3.64% contrasts with a 90 day share price return decline of 13.75% and a 1 year...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/assessing-wuxi-xdc-cayman-sehk2268-valuation-after-new-akari","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4231","LU2488822045.USD","SG9999014674.SGD","ADC","LENZ","DCF","BK4139","BK4539","BK1141","BK4007","02268","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626878571","title":"Akari CEO says WuXi XDC partnership accelerates AKTX-101 IND toward late 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626878571","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626878571?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:54","pubTimestamp":1775739282,"startTime":"0","endTime":"0","summary":"Akari CEO Abizer Gaslightwala outlined strategic partnership with WuXi XDC in a Virtual Investor “What This Means” interview.Gaslightwala framed partnership as validation of Akari PH1 spliceosome-modulating payload platform for antibody-drug conjugates.Management expects collaboration to accelerate lead program AKTX-101 toward an IND filing in late 2026.Interview described deal as extending beyond a standard contract manufacturer relationship, aiming to reduce development execution risk.Akari positioned partnership as strengthening its footing in a more active ADC deal market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 09, 2026, and is s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL3M7MKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0516423174.USD","LU0823426480.USD","LU0359202008.SGD","LU0516423091.SGD","LU1242518857.USD","LU0051755006.USD","LU0052750758.USD","SG9999002562.SGD","LU1688375341.USD","LU0516422952.EUR","SG9999014674.SGD","LU2039709279.SGD","BK1589","LU0456846285.SGD","LU0417516902.SGD","LU0456827905.SGD","LU0320764599.SGD","LU0708995583.HKD","LU1242518931.SGD","LU0516422440.USD","LU0819121731.USD","LU0979878070.USD","LU0588546209.SGD","LU0327786744.USD","LU0181495838.USD","LU0326950275.SGD","02268","LU0572944931.SGD","LU1794554557.SGD","LU0043850808.USD","BK4007","LU0417516738.SGD","BK1610","LU0348735423.USD","IE00B0JY6N72.USD","LU2488822045.USD","LU3063872942.SGD","LU0307460666.USD","BK1521","LU0856984785.SGD","SG9999002463.SGD","LU0359201612.USD","LU0140636845.USD","LU0348825331.USD","LU0516422366.SGD","AKTX","02269","LU1880383366.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143415909","title":"WUXI XDC Issues 1.203 Million Shares Following Option Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1143415909","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143415909?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:10","pubTimestamp":1775653813,"startTime":"0","endTime":"0","summary":"WUXI XDC (02268) announced that on April 8, 2026, a total of 1.203 million ordinary shares were issued pursuant to the exercise of options under the pre-IPO share option scheme.","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268","LU2488822045.USD","SG9999014674.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180212203","title":"WuXi XDC approves 4.85 million restricted shares for 425 staff under 2024 scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1180212203","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180212203?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:04","pubTimestamp":1775653440,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman Inc. has authorised the issue of 4.85 million restricted shares on 8 April 2026 under its 2024 Share Scheme. The grant covers 425 participants, comprising three executive directors...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625941077","title":"WuXi XDC files HKEX next-day return, issues 1,507,353 shares at HKD 1.8-7.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2625941077","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625941077?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:01","pubTimestamp":1775653289,"startTime":"0","endTime":"0","summary":"WuXi XDC filed a next-day disclosure return showing issuance of 1,507,353 new ordinary shares via employee share option exercises between April 1 and April 8.Issue prices ranged from HKD 1.80 to HKD 7.50 per share.Issued shares rose to 1,260,343,250 as of April 8 from 1,258,835,897 on March 31.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL3gHWCr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0819121731.USD","LU0516423091.SGD","LU1880383366.USD","LU0327786744.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU0051755006.USD","SG9999014674.SGD","LU0043850808.USD","LU0348825331.USD","LU0856984785.SGD","LU0516422952.EUR","LU0823426480.USD","LU0140636845.USD","LU0417516738.SGD","LU0979878070.USD","LU0516423174.USD","LU1794554557.SGD","BK1521","LU0359201612.USD","LU0456846285.SGD","LU2488822045.USD","LU0181495838.USD","LU1242518931.SGD","LU0359202008.SGD","LU0052750758.USD","LU0588546209.SGD","LU2039709279.SGD","LU3063872942.SGD","BK1610","LU0320764599.SGD","LU0326950275.SGD","LU0039217434.USD","LU0456827905.SGD","LU1688375341.USD","LU0572944931.SGD","LU0516422366.SGD","LU0417516902.SGD","LU1720050803.USD","BK1589","BK1141","02268","LU0348735423.USD","SG9999002463.SGD","LU0307460666.USD","LU0708995583.HKD","LU1242518857.USD","SG9999002562.SGD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625411529","title":"WuXi XDC grants 4,854,500 nil-cost restricted shares under 2024 scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2625411529","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625411529?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:55","pubTimestamp":1775652934,"startTime":"0","endTime":"0","summary":"WuXi XDC granted 4,854,500 restricted shares under its 2024 share scheme on April 8, 2026.Awards went to 425 grantees, including 3 executive directors.Purchase price set at nil; shares closed at HK$ 60.65 on grant date.Vesting set at 25% on each anniversary of grant date.Directors received 364,200 restricted shares in total, including 155,300 to CEO Jincai Li.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi XDC Cayman Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1frDrv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0819121731.USD","LU0516423091.SGD","LU1880383366.USD","LU0327786744.USD","IE00B0JY6N72.USD","LU0823426308.USD","LU0051755006.USD","SG9999014674.SGD","LU0043850808.USD","LU0348825331.USD","LU0856984785.SGD","LU0516422952.EUR","LU0823426480.USD","LU0140636845.USD","BK1576","LU0417516738.SGD","LU0979878070.USD","LU0516423174.USD","LU1794554557.SGD","BK1521","LU0359201612.USD","LU0456846285.SGD","LU2488822045.USD","LU0181495838.USD","LU0359202008.SGD","LU0052750758.USD","LU0588546209.SGD","LU2039709279.SGD","LU3063872942.SGD","BK1610","LU0320764599.SGD","LU0326950275.SGD","LU0039217434.USD","LU0456827905.SGD","LU1688375341.USD","LU0572944931.SGD","LU0516422366.SGD","LU0417516902.SGD","LU1720050803.USD","BK1141","BK1589","02268","LU0348735423.USD","SG9999002463.SGD","LU0307460666.USD","LU0708995583.HKD","LU1242518857.USD","SG9999002562.SGD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187004752","title":"WuXi XDC Adds 0.84 Million Shares in March 2026 as Pre-IPO Options Are Exercised","url":"https://stock-news.laohu8.com/highlight/detail?id=1187004752","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187004752?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:22","pubTimestamp":1775640154,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman Inc. (WuXi XDC) filed its Monthly Return for the period ended 31 March 2026, detailing a modest increase in issued share capital driven entirely by employee option exercises. Key...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625671117","title":"Akari partners with WuXi XDC to accelerate PH1 ADC payload development, IND by 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625671117","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625671117?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:47","pubTimestamp":1775479679,"startTime":"0","endTime":"0","summary":"Akari Therapeutics entered strategic partnership with WuXi XDC to accelerate development of its PH1 antibody-drug conjugate payload targeting RNA splicing.Collaboration targets an IND filing by late 2026.Partnership supports lead program AKTX-101, initially aimed at metastatic urothelial cancer.Akari expects Phase 1 trial for AKTX-101 to start in late 2026 or early 2027, subject to regulatory clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on April 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL3w1p7D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU1688375341.USD","LU0819121731.USD","BK1589","LU0516422366.SGD","LU1880383366.USD","LU0320764599.SGD","LU0348735423.USD","SG9999002562.SGD","LU0051755006.USD","SG9999002463.SGD","BK1610","SG9999014674.SGD","BK1521","LU0039217434.USD","LU0359202008.SGD","LU1242518931.SGD","AKTX","LU0979878070.USD","BK4139","LU0516423091.SGD","LU0572944931.SGD","LU0456846285.SGD","LU0043850808.USD","02269","LU2488822045.USD","IE00B0JY6N72.USD","LU0359201612.USD","LU0140636845.USD","LU0456827905.SGD","LU1242518857.USD","02268","LU0348825331.USD","LU0516423174.USD","LU0823426480.USD","LU0708995583.HKD","LU0516422952.EUR","BK1576","LU0588546209.SGD","LU3063872942.SGD","LU0326950275.SGD","LU0516422440.USD","LU0417516902.SGD","LU0417516738.SGD","LU0181495838.USD","LU0823426308.USD","LU0856984785.SGD","BK4007","LU1720050803.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149528263","title":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149528263","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149528263?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:14","pubTimestamp":1774592089,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio up 7%; Hengrui Pharma and Junshi Bio Up 6%; HBM, Beigene, $Sihuan Pharm(00460)$ Up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"69cd48097efa50f044ce5ac6380125f5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","02137","02359","03347","01672","09688","02268","01276","09966","03759","06978","09606","06606","01093","02157","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148472362","title":"HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148472362","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148472362?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490045,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. XuanzhuBio up 9%; Xtalpi, Lepu Bio and Ascletis up 6%; Akeso up 5%; Skb Bio up 4%. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b776b6268e0a69a5ca2da5ea0fb0b0d4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","02575","09606","01672","06978","09995","06606","09688","02137","09966","03759","02269","02359","02268","02228","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171313463","title":"CLSA Raises Target Price for WUXI XDC to HK$80.9, Citing Improved Profit Visibility","url":"https://stock-news.laohu8.com/highlight/detail?id=1171313463","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171313463?lang=en_us&edition=fundamental","pubTime":"2026-03-25 14:08","pubTimestamp":1774418900,"startTime":"0","endTime":"0","summary":"CLSA released a research report stating that WUXI XDC's (02268) second-half performance last year met expectations, while its 2026 guidance exceeded expectations. Management forecasts at least 35%...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","SG9999014674.SGD","02268","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103809659","title":"CICC Maintains Outperform Rating on WUXI XDC with HK$88.0 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1103809659","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103809659?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:44","pubTimestamp":1774406679,"startTime":"0","endTime":"0","summary":"CICC has released a research report stating that, considering increased costs from the integration of TOT Biopharm and the commencement of production in Singapore, it has kept its 2027 forecast for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","02268","LU2488822045.USD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621006791","title":"WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2621006791","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621006791?lang=en_us&edition=fundamental","pubTime":"2026-03-24 18:03","pubTimestamp":1774346629,"startTime":"0","endTime":"0","summary":"WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago.\nSee...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2268/wuxi-xdc-cayman-shares/news/wuxi-xdc-cayman-sehk2268-margin-slip-tests-bullish-growth-na","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4112","LU2488822045.USD","SG9999014674.SGD","BLSG","02268","BK1141","BLSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104209875","title":"Morgan Stanley Assigns \"Overweight\" Rating to WUXI XDC (02268) with HK$86 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1104209875","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104209875?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:01","pubTimestamp":1774342899,"startTime":"0","endTime":"0","summary":"Morgan Stanley has released a research report indicating that WUXI XDC (02268) achieved revenue of RMB 5.944 billion last year, an increase of 46.7% year-on-year. Gross profit reached RMB 2.139...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","LU2488822045.USD","SG9999014674.SGD","02268"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129513220","title":"From Enabler to Innovator: WUXI XDC's Evolution and Value Transformation in the CRDMO Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1129513220","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129513220?lang=en_us&edition=fundamental","pubTime":"2026-03-24 14:39","pubTimestamp":1774334379,"startTime":"0","endTime":"0","summary":"An impressive annual report has brought the global leader in bioconjugate drug CRDMO, WUXI XDC, into the spotlight. Financial results show that in 2025, the company achieved revenue of RMB 5.94...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","02268","LU2488822045.USD","SG9999014674.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://wuxixdc.com","stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":0.0166},{"period":"3month","weight":-0.1544},{"period":"6month","weight":-0.1766},{"period":"1year","weight":0.5774},{"period":"ytd","weight":-0.0444}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"WuXi XDC Cayman Inc is an investment holding company principally engaged in the provision of comprehensive contract research, development and manufacturing organization (CRDMO) services for antibody drug conjugate (ADC) and other bioconjugates. The Company's services include the discovery, process development and Good Manufacturing Practice (GMP) manufacturing for bioconjugates, monoclonal antibody intermediates and payload-linkers associated with bioconjugates. The Company provides CRDMO services to customers through contracts under fee-for-service (FFS) basis and contracts under full-time equivalent (FTE) basis. The Company principally conducts its businesses in domestic and overseas markets, including North America, Europe and the rest of the world.","yearOnYearQuotes":[{"month":1,"riseRate":0.222222,"avgChangeRate":0.010265},{"month":2,"riseRate":0.666667,"avgChangeRate":0.058284},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.010372},{"month":4,"riseRate":0.555556,"avgChangeRate":0.03555},{"month":5,"riseRate":0.333333,"avgChangeRate":0.006014},{"month":6,"riseRate":0.4,"avgChangeRate":-0.032735},{"month":7,"riseRate":0.4,"avgChangeRate":0.011785},{"month":8,"riseRate":0.4,"avgChangeRate":-0.114063},{"month":9,"riseRate":0.333333,"avgChangeRate":0.019767},{"month":10,"riseRate":0.777778,"avgChangeRate":0.151657},{"month":11,"riseRate":0.333333,"avgChangeRate":0.008796},{"month":12,"riseRate":0.111111,"avgChangeRate":-0.068876}],"exchange":"SEHK","name":"WUXI XDC","nameEN":"WUXI XDC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"WUXI XDC(02268),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest WUXI XDC(02268) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"WUXI XDC,02268,WUXI XDC股票,WUXI XDC股票老虎,WUXI XDC股票老虎国际,WUXI XDC行情,WUXI XDC股票行情,WUXI XDC股价,WUXI XDC股市,WUXI XDC股票价格,WUXI XDC股票交易,WUXI XDC股票购买,WUXI XDC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"WUXI XDC(02268),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest WUXI XDC(02268) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}